Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
Expanded access is no longer available for this treatment.
Information provided by:
First received: September 17, 2010
Last updated: July 5, 2011
Last verified: July 2011
This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus|
Resource links provided by NLM:
Further study details as provided by MacroGenics:
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01206504
Sponsors and Collaborators
|Study Director:||Anastasia Daifotis, M.D.||MacroGenics|